Clinical Trial Update: Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating dapagliflozin as monotherapy in type 2 diabetes patients inadequately controlled with diet and exercise has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Phase 3 | Status: SUSPENDED